ERBB2 and gastroesophageal junction adenocarcinoma: The landmark ToGA study represented a pivotal advancement in this realm, being the first to demonstrate that combining trastuzumab with chemotherapy significantly extends survival in advanced G/GEJ adenocarcinoma patients with Her2 gene amplification.